Question · Q4 2025
Viktor Dziuba asked for an update on ARGX-213, specifically regarding the expectation for Phase 1 results in H1 this year and whether the latest development program would be discussed later this year.
Answer
Karen Massey, Chief Operating Officer, confirmed that ARGX-213 is in the clinic and argenx is actively working on the indication strategy and path forward. She stated that updates will be shared when available.
Ask follow-up questions
Fintool can predict 
ARGX's earnings beat/miss a week before the call